However, for omalizumab, a recent meta-analysis in pediatric patients showed a trend but no statistical significance towards better therapeutic response with higher IgE baseline levels (WMD 50.30, 95% CI: − 5.91 to − 106.51) [ 98 ], therefore making the role for IgE as a biomarker for prediction of treatment response uncertain.
← all excerpts
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
1
—
—